Drug Trial Radar · NCT07246031
BPC2001 for the Prevention of Acute Graft-Versus-Host Disease Following Haploidentical Stem Cell Transplantation
Last checked: Nov 19, 2026Latest source record: Aug 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
50
Planned (sponsor's estimate)
Start
Oct 29, 2025
Primary completion
Apr 30, 2028
Study completion Dec 31, 2028
Sponsor
- Lead sponsor
- BioPhoenix Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Nov 24, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A Phase IIb open label study evaluates the safety and efficacy of repeat doses of BPC2001 in combination with standard of care treatment for the prevention of acute graft-vs-host-disease (aGvHD) in subjects following Haploidentical Stem Cell Transplantation (Haplo-SCT).
Conditions
- Graft -Versus-host-disease
- aGVHD
- Haploidentical Stem Cell Transplantation
- cGVHD
Interventions
BPC-2001Drug
Subjects will receive 6 weekly doses of BPC2001, 100 μg/kg via IV administration after completion of Haplo-SCT.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Grades II-IV aGVHDTime frame: Day 100 after the last infusion of stem cell
- AE of BPC2001 in addition to the graft-versus-host disease (GvHD) prophylaxis regimenTime frame: 1 year post-transplant
- SAE of BPC2001 in addition to the graft-versus-host disease (GvHD) prophylaxis regimenTime frame: 1 year post-transplant
- Lab test values of BPC2001 in addition to the graft-versus-host disease (GvHD) prophylaxis regimenTime frame: 1 year post-transplant
- Vital sign of BPC2001 in addition to the graft-versus-host disease (GvHD) prophylaxis regimenTime frame: 1 year post-transplant
- Graft failure of BPC2001 in addition to the graft-versus-host disease (GvHD) prophylaxis regimenTime frame: 1 year post-transplant
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Tongji Medical College of Huazhong University of Science and Technology
Wuhan, China · Recruiting
Peking University People's Hospital
Beijing, Beijing Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.